1. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
   Xiuman Zhou et al, 2020, Cell Communication and Signaling CrossRef
2. Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
   Elisa Giannetta et al, 2021, Frontiers in Endocrinology CrossRef
3. PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives
   Francesca SANGUEDOLCE et al, 2021, Minerva Respiratory Medicine CrossRef
4. Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis
   Kunmin Xiao et al, 2021, Journal of Immunology Research CrossRef
5. Peptide-based PET imaging agent of tumor TIGIT expression
   Dinghu Weng et al, 2023, EJNMMI Research CrossRef
6. Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance
   Shuyan He et al, 2024, Critical Reviews in Eukaryotic Gene Expression CrossRef
7. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
   Danielle Brazel et al, 2023, Lung Cancer: Targets and Therapy CrossRef
8. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
   Huarong Cai et al, 2020, Frontiers in Oncology CrossRef
9. Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer
   Shili Yu et al, 2021, Frontiers in Medicine CrossRef
10. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis
    Dan Zhang et al, 2022, World Journal of Surgical Oncology CrossRef
11. Prognostic value of TIGIT in East Asian patients with solid cancers: A systematic review, meta-analysis and pancancer analysis
    Sicong Li et al, 2022, Frontiers in Immunology CrossRef